Cargando…
Severe Multi-Resistant Pemphigus vulgaris: prolonged remission with a single cycle of Rituximab
Pemphigus vulgaris is an autoimmune bullous disease whose therapy is based on systemic corticosteroids, with or without immunosuppressants. Rituximab is a chimeric monoclonal antibody of the IgG class, directed at a specific CD20 B cell surface antigen, used in pemphigus vulgaris empirically since 2...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Dermatologia
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3760947/ https://www.ncbi.nlm.nih.gov/pubmed/24068143 http://dx.doi.org/10.1590/abd1806-4841.20131990 |
_version_ | 1782282828567805952 |
---|---|
author | Corral, Isabela Soubhia de Freitas, Thais Helena Proença de Aquino, Renata Telles Rudge Koller, Daniella Abbruzzini S. Magliari, Maria Elisa Ruffolo Muller, Helena |
author_facet | Corral, Isabela Soubhia de Freitas, Thais Helena Proença de Aquino, Renata Telles Rudge Koller, Daniella Abbruzzini S. Magliari, Maria Elisa Ruffolo Muller, Helena |
author_sort | Corral, Isabela Soubhia |
collection | PubMed |
description | Pemphigus vulgaris is an autoimmune bullous disease whose therapy is based on systemic corticosteroids, with or without immunosuppressants. Rituximab is a chimeric monoclonal antibody of the IgG class, directed at a specific CD20 B cell surface antigen, used in pemphigus vulgaris empirically since 2002, with success in 90% of the cases and long periods of remission. Male patient, 33 years old, diagnosed with pemphigus vulgaris, confirmed by histopathology and direct immunofluorescence. He was treated for seven months with numerous treatments, including immunosuppressive drugs, with an unsatisfactory response, until he had complete remission with the use of rituximab. During a 34-month follow-up period, the patient presented a slight clinical relapse, which was successfully controlled with prednisone in a daily dose of 120mg, soon reduced to 20mg. |
format | Online Article Text |
id | pubmed-3760947 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Sociedade Brasileira de Dermatologia |
record_format | MEDLINE/PubMed |
spelling | pubmed-37609472013-09-16 Severe Multi-Resistant Pemphigus vulgaris: prolonged remission with a single cycle of Rituximab Corral, Isabela Soubhia de Freitas, Thais Helena Proença de Aquino, Renata Telles Rudge Koller, Daniella Abbruzzini S. Magliari, Maria Elisa Ruffolo Muller, Helena An Bras Dermatol Case Report Pemphigus vulgaris is an autoimmune bullous disease whose therapy is based on systemic corticosteroids, with or without immunosuppressants. Rituximab is a chimeric monoclonal antibody of the IgG class, directed at a specific CD20 B cell surface antigen, used in pemphigus vulgaris empirically since 2002, with success in 90% of the cases and long periods of remission. Male patient, 33 years old, diagnosed with pemphigus vulgaris, confirmed by histopathology and direct immunofluorescence. He was treated for seven months with numerous treatments, including immunosuppressive drugs, with an unsatisfactory response, until he had complete remission with the use of rituximab. During a 34-month follow-up period, the patient presented a slight clinical relapse, which was successfully controlled with prednisone in a daily dose of 120mg, soon reduced to 20mg. Sociedade Brasileira de Dermatologia 2013 /pmc/articles/PMC3760947/ /pubmed/24068143 http://dx.doi.org/10.1590/abd1806-4841.20131990 Text en ©2013 by Anais Brasileiros de Dermatologia http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Corral, Isabela Soubhia de Freitas, Thais Helena Proença de Aquino, Renata Telles Rudge Koller, Daniella Abbruzzini S. Magliari, Maria Elisa Ruffolo Muller, Helena Severe Multi-Resistant Pemphigus vulgaris: prolonged remission with a single cycle of Rituximab |
title | Severe Multi-Resistant Pemphigus vulgaris: prolonged remission with a
single cycle of Rituximab |
title_full | Severe Multi-Resistant Pemphigus vulgaris: prolonged remission with a
single cycle of Rituximab |
title_fullStr | Severe Multi-Resistant Pemphigus vulgaris: prolonged remission with a
single cycle of Rituximab |
title_full_unstemmed | Severe Multi-Resistant Pemphigus vulgaris: prolonged remission with a
single cycle of Rituximab |
title_short | Severe Multi-Resistant Pemphigus vulgaris: prolonged remission with a
single cycle of Rituximab |
title_sort | severe multi-resistant pemphigus vulgaris: prolonged remission with a
single cycle of rituximab |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3760947/ https://www.ncbi.nlm.nih.gov/pubmed/24068143 http://dx.doi.org/10.1590/abd1806-4841.20131990 |
work_keys_str_mv | AT corralisabelasoubhia severemultiresistantpemphigusvulgarisprolongedremissionwithasinglecycleofrituximab AT defreitasthaishelenaproenca severemultiresistantpemphigusvulgarisprolongedremissionwithasinglecycleofrituximab AT deaquinorenatatellesrudge severemultiresistantpemphigusvulgarisprolongedremissionwithasinglecycleofrituximab AT kollerdaniellaabbruzzinis severemultiresistantpemphigusvulgarisprolongedremissionwithasinglecycleofrituximab AT magliarimariaelisaruffolo severemultiresistantpemphigusvulgarisprolongedremissionwithasinglecycleofrituximab AT mullerhelena severemultiresistantpemphigusvulgarisprolongedremissionwithasinglecycleofrituximab |